Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Clinical ResearchPhase 1 - Phase 4 FDA’s Push for DEI in Clinical Trials: What Sponsors Need to Know in 2024 By Stacy Weil January 11, 2024 Clinical ResearchPhase 1 - Phase 4 7 Reasons to Ditch Traditional Monitoring in Favor of a Centralized Strategy By Nicole Stansbury January 3, 2024 Clinical ResearchPhase 1 - Phase 4 Data at Your Fingertips: The Case for Centralized Monitoring By Nicole Stansbury December 14, 2023 Clinical ResearchPhase 1 - Phase 4 Patient-Centered Hematological Malignancy Trials: A Blueprint for Success By Ashley Herrick December 5, 2023 Consulting CMC Considerations for Pre-IND Meetings By Ryan Key November 29, 2023 Clinical ResearchPhase 1 - Phase 4 8 Cost Containment Strategies for Rare Disease Clinical Trials By Leslie Wetherell November 21, 2023 Previous 1 2 3 4 5 6 … 56 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today